BioCentury This Week

BioCentury

378 - Ep. 368 - ASCO Preview, China Policy, ADC Linkers

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

378 - Ep. 368 - ASCO Preview, China Policy, ADC Linkers

00:00

Episodios

mar., 26 mayo 2026

lun., 18 mayo 2026

mar., 12 mayo 2026

lun., 11 mayo 2026

lun., 04 mayo 2026

lun., 27 abr. 2026

mié., 22 abr. 2026

lun., 20 abr. 2026

lun., 13 abr. 2026

lun., 06 abr. 2026

mié., 01 abr. 2026

lun., 30 mar. 2026

lun., 23 mar. 2026

lun., 16 mar. 2026

vie., 13 mar. 2026

lun., 09 mar. 2026

lun., 02 mar. 2026

lun., 23 feb. 2026

mar., 17 feb. 2026

lun., 09 feb. 2026

lun., 02 feb. 2026

lun., 26 ene. 2026

jue., 22 ene. 2026

mar., 20 ene. 2026

jue., 15 ene. 2026

lun., 12 ene. 2026

lun., 05 ene. 2026

lun., 29 dic. 2025

lun., 15 dic. 2025

lun., 08 dic. 2025

lun., 01 dic. 2025

lun., 24 nov. 2025

vie., 21 nov. 2025

jue., 20 nov. 2025

lun., 17 nov. 2025

mié., 12 nov. 2025

lun., 10 nov. 2025

lun., 03 nov. 2025

vie., 31 oct. 2025

lun., 27 oct. 2025

lun., 20 oct. 2025

mié., 15 oct. 2025

lun., 13 oct. 2025

lun., 06 oct. 2025

lun., 29 sep. 2025

mié., 24 sep. 2025

mar., 23 sep. 2025

lun., 22 sep. 2025

lun., 15 sep. 2025

lun., 08 sep. 2025

BioCentury This Week

Episodios

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Ep. 367 - FDA, obesity targets and the rise of DACs

Ep. 366 - Europe's need for speed: Bio€quity takeaways

Ep. 365 - Thin ice for Makary, redosing AAVs

Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

Ep. 362 - AACR: Data and de-risking

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Ep. 358 - Europe's biotech challenge

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Ep. 354 - East-West Summit Takeaways

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

Ep. 346 - 2026 Public Markets Preview

Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

Ep. 342 - 2026 Biotech Kickoff

Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

Ep. 340 - Obesity Data, Kymera & FDA Survey Results

Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult

Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding

Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc

Ep. 336 - Cautious Optimism and M&A Momentum

Ep. 335 - Neurology's Coming Inflection Point

Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi

Ep. 333 - Is This Korea’s Biotech Moment?

Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA

Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster

Ep. 330 - China's Innovation Moment

Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors

Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers

Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg

Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A

Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund

Ep. 324 - Genmab, GSK and Drug Pricing

Ep. 323 - Agentic AI: From New Targets to the Clinic

Ep. 322 - Takeaways from BioCentury Grand Rounds Europe

Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus

Ep. 320 - U.K. Biotech, U.S.-China, Insmed

Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more

Más podcasts de Ciencias

Más podcasts internacionales de Ciencias